Methods of treating blood disorders with monospecific antibodies targeting VWF

By developing a monospecific antibody against VWF protein, the problem of VWF protein accumulation in blood diseases is solved, and plasma levels are reduced, providing a new method to treat blood diseases.

CN119032109APending Publication Date: 2024-11-26HEMAB APS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034172.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-08
Filing Date
2023-02-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat blood disorders associated with vasophilia factor (VWF), especially due to the accumulation of plasma levels of VWF protein.

Method used

A monospecific antibody was developed to target antigen binding sites in the cysteine ​​junction (CK) domain and fragment crystallizable (Fc) region of VWF protein, which leads to the accumulation of VWF protein in plasma, The antibodies may be of a monovalent or modified type, including specific mutation sites to improve binding efficacy.

Benefits of technology

Through specific binding, antibodies can effectively reduce the plasma level of VWF protein, providing a new method to treat blood disorders and improve disease control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032109A_ABST
    Figure CN119032109A_ABST
Patent Text Reader

Abstract

Provided herein are antibodies that bind to an epitope of a von willebrand factor that is located in the cysteine knot (CK) domain. Such antibodies may be used in methods of treatment that treat one or more blood conditions characterized by excessive bleeding.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 268,040, filed February 15, 2022, and U.S. Provisional Application No. 63 / 269,000, filed March 8, 2022, the entire contents of which are incorporated herein by reference.

[0003] Sequence Listing

[0004] This application contains a sequence listing, which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy created on February 7, 2023 is named "HMT_002WO_SequenceListing.xml" and is 457,851 bytes in size.

[0005] Overview of public content

[0006] Disclosed herein, in certain embodiments, are compositions and methods for treating hematological disorders using monospecific antibodies targeted to von Willebrand Factor (VWF).

[0007] In certain embodiments, disclosed herein are monospecific antibodies comprising an antigen binding site that specifically binds to an epitope of a von Willebrand Factor (VWF) protein located in the cysteine ​​knot (CK) domain and the fragment crystallizable (Fc) region, wherein binding of the antibodies disclosed herein to the VWF protein results in accumulation of the VWF protein in the plasma compared to the plasma level of the VWF protein in the absence of the antibody. In some embodiments, the antibodies disclosed herein are monovalent antibodies. In some embodiments, the Fc region is a wild-type Fc region. In some embodiments, the Fc region is a modified Fc region. In some embodiments, the modified Fc region comprises one or more mutations selected from the group consisting of: R435H mutation, N434A mutation, T252L / T253S / T254F mutation, E294delta / T307P / N434Y mutation, T256N / A378V / S383N / N434Y mutation, E294delta mutation, M252Y / S254T / T256E mutation, M428L / N434S mutation, T307A / E380A / N434A mutation, T250Q / M428 L mutation, T250Q / M428F mutation, T250E / M428F mutation, T250E / M428L mutation, T256D / Q311V / A378V mutation, T256D / H286D / T307R / Q311V / A378V mutation, H285N / T307Q / N315D mutation, T307Q / Q311V / A378V mutation, H285D / T307Q / A378V mutation, L234F / L235E / P331S mutation, L234F / L235Q / K322Q mutation, L 234F / L235Q / P331G mutation, L234F / L235A / K322Q mutation, S228P / F234A / L235A / G237A / P238S mutation, L234A / L235E / G237A / A330S / P331S mutation, F243A / V264A mutation, S228P / L235E / P329G mutation, M252Y / M428L mutation, D259I / V308F mutation, T307Q / N434S mutation, M428L / V308F mutation, Q311V / N434S mutation, H433K / N434F mutation, E258F / V427T mutation, K288E / H435K mutation, F234A / L235A mutation, F234A / L235A / S228P mutation, L234A / L235A / P329G mutation, F234A / L235A / P329G mutation, P329G mutation, F234 mutation, S228P mutation, delta-K447 mutation, L235A mutation, L235E mutation, V308P mutation, V308W mutation, V308Y mutation,V308F mutation, N434S mutation, T307 mutation, Q312A mutation, K322A mutation, P329A mutation, P331A mutation, P238A mutation, D265A mutation, D269A mutation, D270A mutation, N297A mutation, A327Q mutation, P329A mutation, S239A mutation, E294A mutation, Q295A mutation, V303A mutation, A330R mutation, T299A mutation, F234A mutation, T366W mutation, T366S mutation, L368A mutation, Y407V mutation, F405L mutation, K409R mutation, F405L / R409K mutation, and any combination thereof. In some embodiments, the Fc region comprises an N-terminal truncation (e.g., truncation of the N-terminal residues, or more). In some embodiments, the antibody is a human IgG4 antibody comprising a first heavy chain and a second heavy chain. In some embodiments, the first heavy chain comprises S228P / T366W / F234A / L235A / delta-K447 mutations, and the second heavy chain comprises S228P / T366S / L368A / Y407V / F234A / L235A / delta-K447 mutations. In some embodiments, the first heavy chain comprises S228P / T366W / delta-K447 mutations, and the second heavy chain comprises S228P / T366S / L368A / Y407V / delta-K447 mutations. In some embodiments, the first heavy chain and the second heavy chain further comprise M252Y / S254T / T256E mutations. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 12 and a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 16.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 15; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 12, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 13,a variable light (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 16, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 453; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 473; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:463 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 19 and a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 23.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 23. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24,CDR L2 having an amino acid sequence 100% identical to that of AAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO:25. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 19, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 22; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 19, NO:23 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:24, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:25. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 454; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 474; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:464 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:26 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 30.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 29; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 26, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 29; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 26. NO:30 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:31, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:31, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:32. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:33.%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 37 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 34,a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 35, a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 36, and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDRL2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 39. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 33, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 36; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 33; NO:37 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:38, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:39. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 455; and a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 475;and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 465; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 465. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:40 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:40 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 44.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 43; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 46. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 40, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 43; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 40. NO:44 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:44, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:45,CDR L2 having an amino acid sequence 100% identical to that of GSS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO:46. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 456; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 476; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:466 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 47 and a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 51.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 50; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 47, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 48,a variable light (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 51 and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:54 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:54 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 54 and a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 58.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 57; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 60. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 54, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 57; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 54. NO:58 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or higher) amino acid sequence, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 60. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 457; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 477; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:467 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:61 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 61 and a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 65.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 64; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDRL2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 61, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 62,a variable light (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 65, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 68 and a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 72.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 71; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 68, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 71; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO: 72 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or higher) amino acid sequence, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:75 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:75 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 79.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 79. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 78; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 81. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 75, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 78; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 75. NO:79 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:80, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:81. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:82.%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 86 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:82 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:82 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 86. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 83,a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 85; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 82, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 85; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 82. NO:86 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:87, a CDRL2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:88. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 89 and a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 93.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:89 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 93. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 94,CDR L2 having an amino acid sequence 100% identical to that of GAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO:95. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 89, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 92; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 89, NO:93 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:94, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:95. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 458; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 478; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:468 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 96 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 100.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 99; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 96, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 99; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 96. NO: 100 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 100, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 103.%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 107 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the antibody comprises a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 104,a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 106; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 109. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 103, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 106; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 103, NO:107 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:108, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:109. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 110 and a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 114.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 116. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 110, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 113; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 110. ID NO: 114 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 116. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 459; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 479; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:469 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or higher) amino acid sequences. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 117 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 121.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 121. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 120; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 117, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 120; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 117. NO: 121 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 121, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 122,CDR L2 having an amino acid sequence 100% identical to that of DAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 123. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 124 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 128.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 128. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 127; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 130. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 124, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 127; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 124; NO:128 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:128, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:129,CDR L2 having an amino acid sequence 100% identical to that of EAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 130. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 131 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 135.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 134; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 137. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 131, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 134; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 131; NO:135 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:135, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:136,CDR L2 having an amino acid sequence 100% identical to that of DAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 137. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 138 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 142.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 142. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 141; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 138, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 141; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 138. NO:142 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:142, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:143,CDR L2 having an amino acid sequence 100% identical to that of DAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 144. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 145 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 149.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 149. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 148; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 151. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 145, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 148; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 145. NO: 149 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 150, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 150,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 151. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 152 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 156.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 156. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 155; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 158. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 152, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 155; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 156. NO:156 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:157, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:157,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 158. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 159 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 163.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 163. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 162; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 165. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 159, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 162; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 159, NO: 163 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 163, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 164,CDR L2 having an amino acid sequence 100% identical to that of DAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 165. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 166 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 170.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 170. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 169; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 172. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 166, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 169; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 167; NO: 170 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 170, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 171,CDR L2 having an amino acid sequence 100% identical to that of GAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 172. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 173 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 177.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 177. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 176; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 173, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 176; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 173; NO: 177 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 178, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 178,CDR L2 having an amino acid sequence 100% identical to that of GAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 179. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 180 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 184.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 184. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 183; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 186. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 180, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 183; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 181; NO: 184 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 184, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 185,CDR L2 having an amino acid sequence 100% identical to that of DVS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 186. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 187 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 191.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 191. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 190; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 193. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 187, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 190; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 187. NO: 191 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 191, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 192,CDR L2 having an amino acid sequence 100% identical to that of DAT and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 193. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 194 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 198.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 198. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 197; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 200. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 194, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 197; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 194. NO: 198 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 198, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 199,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 200. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 201 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 205.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 205. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 204; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 207. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 201, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 204; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 201; NO:205 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:206, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:206,CDR L2 having an amino acid sequence 100% identical to that of GVD and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 207. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 212. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 211; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 213, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 214. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 211; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208. NO:212 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:213, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:213,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 214. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 215 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 219.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 219. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 218; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 221. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 215, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 218; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 215. NO:219 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:220, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:220,CDR L2 having an amino acid sequence 100% identical to that of GAT, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 221. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 222 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 226.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 226. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 225; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 228. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 222, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 225; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 226. NO:226 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:227, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:227,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 228. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 229 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 233.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 233. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 232; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 235. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 229, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 232; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 229. NO:233 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:234, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:234,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 235. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 236 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 240.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 240. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 239; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 242. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 236, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 239; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 237; NO:240 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:240, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:241,CDR L2 having an amino acid sequence 100% identical to that of GAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 242. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 243 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 247.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 247. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 246; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 249. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 243, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 246; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 243; NO:247 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:248, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:248,CDR L2 having an amino acid sequence 100% identical to that of GAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 249. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 460; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 480; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:470 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 250 and a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 254.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 254. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 253; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 256. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 250, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 251,a variable light (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 254, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 256. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 257 and a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 261.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 261. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 260; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDRL3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 263. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 257, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 260; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 257. NO: 261 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or higher) amino acid sequence, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 263. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 264 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 268.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 268. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 267; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 270. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 264, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 267; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 264. NO:268 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:268, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:269,CDR L2 having an amino acid sequence 100% identical to that of DAV and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 270. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 271 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 275.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 275. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 274; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 277. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 271, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 274; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 271; NO:275 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:276, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:276,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 277. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 282. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 281; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 284. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 281; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278. NO:282 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:283, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:283,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 284. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 285 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 289.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 289. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 288; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 291. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 285, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 288; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 285. NO:289 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:289, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:290,CDR L2 having an amino acid sequence 100% identical to that of GAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 291. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 292 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 296.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 296. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 295; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 298. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 292, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 295; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 296. NO:296 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:296, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:297,CDR L2 having an amino acid sequence 100% identical to that of KAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 298. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 299 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 303.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 303. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 302; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 305. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 299, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 302; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 299, NO:303 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:303, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:304,CDR L2 having an amino acid sequence 100% identical to that of AAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 305. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 306 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 310.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 310. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 309; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 312. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 306, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 309; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 306. NO:310 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:310, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:311,CDR L2 having an amino acid sequence 100% identical to that of DTS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 312. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 461; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 481; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: NO:471 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 313 and a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 317.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 317. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 316; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDRL3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 319. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 313, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 314,a variable light (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 317, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 319. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 320 and a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 324.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 324. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 323; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 326. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 320, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 323; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 321; NO:324 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or higher) amino acid sequence, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 326. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 327 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 331.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 331. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 330; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 327, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 330; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 327. NO:331 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:331, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:332,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 333. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 338.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 338. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 337; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 340. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 337; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334. NO:338 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:338, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:339,CDR L2 having an amino acid sequence 100% identical to that of GAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 340. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 341 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 345.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 344; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 341, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 344; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 341; NO:345 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:346, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:346,CDR L2 having an amino acid sequence 100% identical to that of DAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 347. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 348 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 352.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 351; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DTA, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 354. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 348, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 351; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 348. NO:352 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:353, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:353,CDR L2 having an amino acid sequence 100% identical to that of DTS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 354. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 355 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 359.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 358; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 361. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 355, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 358; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 356. NO:359 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:360, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:360,CDR L2 having an amino acid sequence 100% identical to that of AAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 361. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 362 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 366.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 366. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 365; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 368. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 362, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 365; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 366. NO:366 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:367, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:367,CDR L2 having an amino acid sequence 100% identical to that of AAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 368. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 369 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 373.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 373. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 372; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 375. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 369, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 372; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 369, NO:373 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:373, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:374,CDR L2 having an amino acid sequence 100% identical to that of GTS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 375. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 376 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 380.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 379; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 382. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 376, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 379; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 378; NO:380 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:381, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:381,CDR L2 having an amino acid sequence 100% identical to that of ETS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 382. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 387. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 386; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 389. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 386; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383; NO:387 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:388, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:388,CDR L2 having an amino acid sequence 100% identical to that of GAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 389. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 390 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 394.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 394. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 393; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 396. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 390, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 393; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 390. NO:394 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:394, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:395,CDR L2 having an amino acid sequence 100% identical to that of DAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 396. In some embodiments, the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 462; a second heavy chain region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 482; and a light chain (LC) region comprising an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: ID NO: 472 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 397 and a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 401.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 401. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 400; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDRL3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 403. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 397, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 398,a variable light (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 401 and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 403. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404 and a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 408.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 408. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 407; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDRL3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 410. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 407; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404. NO: 408 has at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99% or higher) amino acid sequence, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 410. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 411 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 415.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 415. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 414; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 417. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 411, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 414; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 412; NO:415 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:416, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:416,CDR L2 having an amino acid sequence 100% identical to that of DAF and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 417. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 418 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 422.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 422. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 421; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 424. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 418, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 421; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 418. NO:422 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:423, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:423,CDR L2 having an amino acid sequence 100% identical to that of DAS, and CDR L3 having an amino acid sequence 100% identical to that of SEQ ID NO: 424. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 425 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 429.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 429. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 428; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 431. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 425, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 428; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 425. NO:429 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:429, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:430,CDR L2 having an amino acid sequence 100% identical to that of DAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 431. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 432 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 436.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 436. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 435; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 438. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 432, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 435; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 432. NO:436 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:437, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:437,CDR L2 having an amino acid sequence 100% identical to that of GAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 438. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 439 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 443.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 443. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 442; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 445. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 439, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 442; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 439, NO:443 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:443, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:444,CDR L2 having an amino acid sequence 100% identical to that of AAS and CDRL3 having an amino acid sequence 100% identical to that of SEQ ID NO: 445. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 446 and a variable heavy chain (VH) region having an amino acid sequence that is at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 450.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 450. In some embodiments, the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 449; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 452. In some embodiments, the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 446, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDRH3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 449; and (b) a variable light chain (VL) region having an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 447; NO: 450 has an amino acid sequence that is at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical, and comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DNF, and a CDRL3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 452. In some embodiments, the antibody binds to a region of the VWF CK domain selected from D2726, R2730,In some embodiments, the antibody binds to one or more of the following amino acid residues: K2735, E2744, D2746, K2757, D2763, and T2789 of the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues: D2726, R2730, D2746, and K2757 of the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues: R2730, K2735, E2744, and D2746 of the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues: K2735, D2746, and K2757 of the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues: R2730, D2746, and K2757 of the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues: K2735, E2744, D2746, and D2763 of the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues of the VWF CK domain: R2730, K2735, E2744, D2746, K2757, and D2763. In some embodiments, the antibody binds to at least amino acid residue K2735 of the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues of the VWF CK domain: D2726, K2735, and K2757. In some embodiments, the antibody binds to at least the following amino acid residues of the VWF CK domain: K2735 and D2763. In some embodiments, the modified Fc region increases the plasma half-life of the antibody compared to the plasma half-life of the antibody lacking the modification in the Fc region. In some embodiments, the modified Fc region increases the plasma half-life of an antibody disclosed herein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to the plasma half-life of an antibody lacking the modification in the Fc region. In some embodiments, the modified Fc region increases the plasma half-life of an antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, %, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%,In some embodiments, the Fc region modified by the present invention reduces the effector function of the antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In some embodiments, the Fc region modified by the present invention reduces the effector function of the antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to the effector function of the antibody lacking modification in the Fc region. In some embodiments, the Fc region modified by the present invention reduces the effector function of the antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to the effector function of the antibody lacking modification in the Fc region. In some embodiments, the modified Fc region reduces one or more effector functions of an antibody disclosed herein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to one or more effector functions of an antibody lacking the modification in the Fc region. In some embodiments, binding of an antibody disclosed herein to a VWF protein does not result in a functional change in the VWF protein. In some embodiments, binding of an antibody disclosed herein to VWF (e.g., to the VWF CK domain) does not inhibit binding of the VWF protein to one or more binding partners. In some embodiments, the one or more binding partners are selected from the group consisting of: factor VIII (FVIII), collagen, glycoprotein Ib (gplb), glycoprotein IIb / IIIa (gpllb / IIIa), and ADAM metallopeptidase with type 1 thrombospondin motif 13 (ADAMTS13). In some embodiments, binding of the antibodies disclosed herein does not inhibit binding of the VWF protein to platelet cells. In some embodiments, accumulation of the VWF protein in the plasma results in plasma levels of the VWF protein that are at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold higher than the plasma level of the VWF protein in the absence of the antibody. In some embodiments, accumulation of the VWF protein in the plasma results in a plasma level of the VWF protein of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 800%, 900%, 1000%, 1500%, 2000%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 6500%, 7000%, 7500%, 80 ...In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein compared to the plasma half-life of the VWF protein in the absence of the antibody. In some embodiments, binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to the plasma half-life of the VWF protein in the absence of the antibody. In some embodiments, binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 800%, 900%, 1000%, 1500%, 2000%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 6500%, 7000%, 8 ... In some embodiments, the binding of an antibody disclosed herein to a VWF protein in plasma results in accumulation of the FVIII protein in the plasma compared to the plasma level of the FVIII protein in the absence of the antibody. In some embodiments, accumulation of FVIII protein in plasma results in plasma levels of FVIII protein that are at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold higher than the plasma levels of FVIII protein in the absence of the antibody. In some embodiments, accumulation of FVIII protein in plasma results in plasma levels of FVIII protein that are at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 350%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 1500%, 2000%, 3500%, 5000%, 6000%, 7000%, 8000%, 9000%, 10000%, 15000%, 20000%, 35000%, 35000%, 50000%, 60000%, 70000%, 80000%, 90000%, 100000%, 15 ...250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000% or more. In some embodiments, binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of a FVIII protein compared to the plasma half-life of the FVIII protein in the absence of the antibody. In some embodiments, binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of a FVIII protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to the plasma half-life of the FVIII protein in the absence of the antibody. In some embodiments, binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the FVIII protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, compared to the plasma half-life of the FVIII protein in the absence of the antibody. In some embodiments, the antibodies disclosed herein specifically bind to a VWF homodimer comprising two VWF monomers linked tail-to-tail by a CK domain linkage. In some embodiments, the antibodies disclosed herein specifically bind to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linker at a 2:1 stoichiometry. In some embodiments, the antibodies disclosed herein specifically bind to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linker at a 2:1 stoichiometry.0.1nM, 0.075nM, 0.05nM, 0.025nM, 0.01nM or less dissociation constant (Kd) binds to the CK domain of the VWF protein. In some embodiments, the antibodies disclosed herein cross-react with the VWF protein of cynomolgus monkeys (Macacafascicularis), house mice (Mus musculus) and / or domestic dogs (Canis familiaris). In some embodiments, the affinity of the antibodies disclosed herein for the VWF protein of cynomolgus monkeys, house mice and / or domestic dogs is at most 10 times lower than the affinity of the antibody for human VWF protein (e.g., at most 10 times, 9 times, 8 times, 7 times, 6 times, 5 times, 4 times, 3 times, 2 times, 1.5 times or lower). In some embodiments, the antibodies disclosed herein are human antibodies, humanized antibodies or chimeric antibodies. In some embodiments, the CK domain is located between amino acid positions 2,723 and 2,813 of SEQ ID NO:1. In some embodiments, the CK domain is a CK domain of a human VWF protein having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence of any one of SEQ ID NOs: 5, 6, 486, or 487. In some embodiments, the CK domain has the amino acid sequence of SEQ ID NO: 5. In some embodiments, the CK domain is a CK domain of a non-human primate (NHP) VWF protein having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence of SEQ ID NO: 6. In some embodiments, the CK domain has the amino acid sequence of SEQ ID NO: 6.

[0008] In certain embodiments, disclosed herein are complexes comprising a VWF protein and a monospecific antibody of the aforementioned aspects and embodiments. In some embodiments, the complex comprises a VWF monomer. In some embodiments, the complex comprises a VWF dimer. In some embodiments, the complex comprises a VWF multimer. In some embodiments, the multimer has a mass of at least 250 kDa (e.g., at least 250 kDa, 500 kDa, 750 kDa, 1000 kDa, 1,250 kDa, 1,500 kDa, 1,750 kDa, 2,000 kDa, 3,000 kDa, 4,000 kDa, 5,000 kDa, 6,000 kDa, 7,000 kDa, 8,000 kDa, 9,000 kDa, 10,000 kDa, kDa, 11,000 kDa, 12,000 kDa, 13,000 kDa, 14,000 kDa, 15,000 kDa, 16,000 kDa, 17,000 kDa, 18,000 kDa, 19,000 kDa, 20,000 kDa, 21,000 kDa, 22,000 kDa, 23,000 kDa, 24,000 kDa, 25,000 kDa or more).

[0009] In certain embodiments, disclosed herein are pharmaceutical compositions comprising the monospecific antibodies of the aforementioned aspects and embodiments and a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of a stabilizer, a buffer, a surfactant, a filler, a solvent, a tonicity or osmotic pressure regulator, an antioxidant, an adjuvant, and an antimicrobial agent.

[0010] In certain embodiments, disclosed herein are methods for treating a blood disorder characterized by excessive bleeding in a subject in need thereof, comprising administering to the subject a monospecific antibody or pharmaceutical composition of the aforementioned aspects and embodiments. In some embodiments, the blood disorder is selected from the group consisting of: von Willebrand disease (VWD), Heydes syndrome, hemophilia A, platelet dysfunction (disorders of platelet function) and connective tissue disorders (connective tissue disorders). In some embodiments, VWD is congenital VWD (cVWD) or acquired VWD (aVWD). In some embodiments, VWD is type 1, type 2A, type 2B, type 2M, type 2N or type 3. In some embodiments, the compositions disclosed herein treat one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) symptoms of a blood disorder selected from the group consisting of: nosebleeds, skin bleeding, bleeding from minor wounds, oral bleeding, angiodysplasia, gastrointestinal bleeding, dental extraction bleeding, postoperative bleeding, heavy menstrual bleeding, obstetric bleeding, hematuria, muscle hematomas, joint bleeding, visceral bleeding, and central nervous system (CNS) bleeding. In some embodiments, the compositions or pharmaceutical compositions disclosed herein promote platelet adhesion, activation, and aggregation in a subject.

[0011] Disclosed herein, in certain embodiments, are methods of accumulating VWF protein in the plasma of a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of the aforementioned aspects and embodiments.

[0012] Disclosed herein, in certain embodiments, are methods of accumulating FVIII protein in the plasma of a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of the aforementioned aspects and embodiments.

[0013] Disclosed herein, in certain embodiments, are methods of increasing the plasma half-life of a VWF protein in a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of the aforementioned aspects and embodiments.

[0014] In certain embodiments, disclosed herein are pharmaceutical compositions comprising monospecific antibodies disclosed herein and pharmaceutically acceptable carriers, diluents or excipients. In some embodiments, pharmaceutically acceptable carriers, diluents or excipients are selected from the group consisting of: stabilizers, buffers, surfactants, fillers, solvents, tension or osmotic pressure regulators, antioxidants, adjuvants and antimicrobials. In some embodiments, pharmaceutical compositions disclosed herein are administered in combination with one or more (e.g., 1, 2, 3, 4, 5 or more) other treatment modalities. In some embodiments, one or more other treatment modalities are one or more therapeutic agents. In some embodiments, the one or more therapeutic agents are selected from the group consisting of: desmopressin (DDAVP), tranexamic acid (TXA), thalidomide, tamoxifen, octreotide, plasma-derived VWF protein concentrate, VWF protein concentrate complexed with FVIII (VWF:FVIII; e.g., Humate P and Wilate), recombinant VWF protein concentrate (e.g., Vonicog alfa), FVIII protein concentrate (e.g., Alphanate and Koate-HP), hormone therapy ...

Claims

1. A monospecific antibody comprising an antigen binding site that specifically binds to an epitope located in the cysteine ​​knot (CK) domain and the fragment crystallizable (Fc) region of a von Willebrand Factor (VWF) protein, wherein binding of the antibody to the VWF protein in plasma results in accumulation of the VWF protein in plasma compared to the plasma level of the VWF protein in the absence of the antibody.

2. The monospecific antibody of claim 1, wherein the antibody is a monovalent antibody.

3. The monospecific antibody according to claim 1 or 2, wherein the Fc region is a wild-type Fc region. The monospecific antibody according to claim 1 , wherein the Fc region is a modified Fc region.

5. The monospecific antibody of claim 4, wherein the modified Fc region comprises one or more mutations selected from the group consisting of: R435H mutation, N434A mutation, T252L / T253S / T254F mutation, E294delta / T307P / N434Y mutation, T256N / A378V / S383N / N434Y mutation, E294delta mutation, M252Y / S254T / T256E mutation, M428L / N434S mutation, T307A / E380A / N434A mutation, T250Q / M428L mutation, T250Q / M428F mutation, T250E / M428F mutation, T250E / M428L mutation, T256D / Q311V / A378V mutation, T256D / H286D / T307R / Q311V / A378V mutation, H285N / T307Q / N315D mutation, T307Q / Q311V / A378V mutation, H285D / T307Q / A378 V mutation, L234F / L235E / P331S mutation, L234F / L235Q / K322Q mutation, L234F / L235Q / P331G mutation, L234F / L235A / K322Q mutation, S228P / F234A / L235A / G237A / P238S mutation, L234A / L235E / G237A / A330S / P331S mutation, F243A / V264A mutation, S228P / L235E / P329G mutation, M252Y / M428L mutation, D259I / V308F mutation, T307Q / N434S mutation, M4 28L / V308F mutation, Q311V / N434S mutation, H433K / N434F mutation, E258F / V427T mutation, K288E / H435K mutation, F234A / L235A mutation, F234A / L235A / S228P mutation, L234A / L235A / P329G mutation, F234A / L235A / P329G mutation, P329G mutation, F234 mutation, S228P mutation, delta-K447 mutation, L235A mutation, L235E mutation, V308P mutation, V308W mutation, V308Y mutation, V308F mutation, N434S mutation, T307 mutation, Q312A mutation, K322A mutation, P329A mutation, P331A mutation, P238A mutation, D265A mutation, D269A mutation, D270A mutation, N297A mutation, A327Q mutation, P329A mutation, S239A mutation, E294A mutation, Q295A mutation, V303A mutation, A330R mutation, T299A mutation, F234A mutation, T366W mutation, T366S mutation, L368A mutation, Y407V mutation, F405L mutation, K409R mutation, F405L / R409K mutation, and any combination thereof.

6. The monospecific antibody according to any one of claims 1 to 5, wherein the modified Fc region is N-terminally truncated.

7. The monospecific antibody of claim 6, wherein the modified Fc region N-terminally truncated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 47, 48, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135 8. The monospecific antibody according to any one of claims 1-7, wherein the antibody is a human IgG4 antibody comprising a first heavy chain and a second heavy chain.

9. The monospecific antibody of claim 8, wherein the first heavy chain comprises S228P / T366W / F234A / L235A / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / F234A / L235A / delta-K447 mutations.

10. The monospecific antibody of claim 8, wherein the first heavy chain comprises S228P / T366W / delta-K447 mutations, and the second heavy chain comprises S228P / T366S / L368A / Y407V / delta-K447 mutations.

11. The monospecific antibody according to claim 9 or 10, wherein the first heavy chain and the second heavy chain further comprise M252Y / S254T / T256E mutations.

12. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

16.

13. The monospecific antibody of any one of claims 1-12, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

16.

14. The monospecific antibody of any one of claims 1-13, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

16.

15. The monospecific antibody of any one of claims 1-14, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

16.

16. The monospecific antibody of any one of claims 1-15, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

16.

17. The monospecific antibody according to any one of claims 1 to 16, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 15; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

18.

18. The monospecific antibody of any one of claims 1 to 17, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 12, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15; a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 16, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:

18.

19. The monospecific antibody of any one of claims 1-18, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 453; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 473; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

463.

20. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

23.

21. The monospecific antibody of any one of claims 1-11 and 20, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

23.

22. The monospecific antibody of any one of claims 1-11, 20 and 21, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

23.

23. The monospecific antibody of any one of claims 1-11 and 20-22, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

23.

24. The monospecific antibody of any one of claims 1-11 and 20-23, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

23.

25. The monospecific antibody of any one of claims 1-11 and 20-24, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 22; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

25.

26. A monospecific antibody according to any one of claims 1-11 and 20-25, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 19, and wherein the variable heavy chain (VH) region comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 22; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 23, and wherein the variable light chain (VL) region comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

25.

27. The monospecific antibody of any one of claims 1-11 and 20-26, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 454; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 474; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

464.

28. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

30.

29. The monospecific antibody of any one of claims 1-11 and 28, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

30.

30. The monospecific antibody of any one of claims 1-11, 28 and 29, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

30.

31. The monospecific antibody of any one of claims 1-11 and 28-30, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

30.

32. The monospecific antibody of any one of claims 1-11 and 28-31, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

30.

33. The monospecific antibody of any one of claims 1-11 and 28-32, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 29; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

32.

34. A monospecific antibody according to any one of claims 1-11 and 28-33, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 26, and wherein the variable heavy chain (VH) region comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 29; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 30, and wherein the variable light chain (VL) region comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

32.

35. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

37.

36. The monospecific antibody of any one of claims 1-11 and 35, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

37.

37. A monospecific antibody according to any one of claims 1-11, 35 and 36, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

37.

38. The monospecific antibody of any one of claims 1-11 and 35-37, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

37.

39. The monospecific antibody of any one of claims 1-11 and 35-38, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

37.

40. The monospecific antibody of any one of claims 1-11 and 35-39, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 36; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

39.

41. A monospecific antibody according to any one of claims 1-11 and 35-40, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 33, and wherein the variable heavy chain (VH) region comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 36; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 37, and wherein the variable light chain (VL) region comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

39.

42. The monospecific antibody of any one of claims 1-11 and 35-41, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 455; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 475; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

465.

43. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

44.

44. The monospecific antibody of any one of claims 1-11 and 43, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

44.

45. The monospecific antibody of any one of claims 1-11, 43 and 44, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

44.

46. ​​The monospecific antibody of any one of claims 1-11 and 43-45, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

44.

47. The monospecific antibody of any one of claims 1-11 and 43-46, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

44.

48. A monospecific antibody according to any one of claims 1-11 and 43-47, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:41, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:42, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:43; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:45, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

46.

49. A monospecific antibody according to any one of claims 1-11 and 43-48, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:40, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:41, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:42, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:43; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:44, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:45, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

46.

50. The monospecific antibody of any one of claims 1-11 and 43-49, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 456; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 476; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

466.

51. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

51.

52. The monospecific antibody of any one of claims 1-11 and 51, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

51.

53. The monospecific antibody of any one of claims 1-11, 51 and 52, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

51.

54. The monospecific antibody of any one of claims 1-11 and 51-53, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

51.

55. The monospecific antibody of any one of claims 1-11 and 51-54, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

51.

56. A monospecific antibody according to any one of claims 1-11 and 51-55, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:48, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:49, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:50; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:52, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

53.

57. A monospecific antibody according to any one of claims 1-11 and 51-56, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:47, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:48, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:49, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:50; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:51, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:52, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

53.

58. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

58.

59. The monospecific antibody of any one of claims 1-11 and 58, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

58.

60. The monospecific antibody of any one of claims 1-11, 58 and 59, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

58.

61. The monospecific antibody of any one of claims 1-11 and 58-60, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

58.

62. The monospecific antibody of any one of claims 1-11 and 58-61, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

58.

63. The monospecific antibody of any one of claims 1-11 and 58-62, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 57; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

60.

64. A monospecific antibody according to any one of claims 1-11 and 58-63, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:54, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:55, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:56, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:57; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:58, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:59, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

60.

65. The monospecific antibody of any one of claims 1-11 and 58-64, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 457; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 577; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

567.

66. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

65.

67. The monospecific antibody of any one of claims 1-11 and 66, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

65.

68. A monospecific antibody according to any one of claims 1-11, 66 and 67, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

65.

69. The monospecific antibody of any one of claims 1-11 and 66-68, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

65.

70. The monospecific antibody of any one of claims 1-11 and 66-69, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

65.

71. A monospecific antibody according to any one of claims 1-11 and 66-70, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 64; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

67.

72. A monospecific antibody according to any one of claims 1-11 and 66-71, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:61, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:62, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:63, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:64; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:65, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:66, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

67.

73. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

65.

74. The monospecific antibody of any one of claims 1-11 and 73, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

65.

75. A monospecific antibody according to any one of claims 1-11, 73 and 74, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO:61 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

65.

76. The monospecific antibody of any one of claims 1-11 and 73-75, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

65.

77. The monospecific antibody of any one of claims 1-11 and 73-76, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

65.

78. The monospecific antibody of any one of claims 1-11 and 73-77, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 64; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

67.

79. A monospecific antibody according to any one of claims 1-11 and 73-78, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:61, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:62, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:63, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:64; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:65, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:66, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

67.

80. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

72.

81. The monospecific antibody of any one of claims 1-11 and 80, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

72.

82. A monospecific antibody according to any one of claims 1-11, 80 and 81, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

72.

83. The monospecific antibody of any one of claims 1-11 and 80-82, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

72.

84. The monospecific antibody of any one of claims 1-11 and 80-83, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

72.

85. The monospecific antibody of any one of claims 1-11 and 80-84, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 71; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

74.

86. A monospecific antibody according to any one of claims 1-11 and 80-85, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 68, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 71; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 72, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

74.

87. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

79.

88. The monospecific antibody of any one of claims 1-11 and 87, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

79.

89. A monospecific antibody according to any one of claims 1-11, 87 and 88, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO:75 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

79.

90. The monospecific antibody of any one of claims 1-11 and 87-89, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

79.

91. The monospecific antibody of any one of claims 1-11 and 87-90, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

79.

92. A monospecific antibody according to any one of claims 1-11 and 87-91, wherein the antibody comprises: a VH comprising a complementary determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 78; and a VL comprising a complementary determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

81.

93. A monospecific antibody according to any one of claims 1-11 and 87-92, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 75, and comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 78; a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 79, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

81.

94. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

86.

95. The monospecific antibody of any one of claims 1-11 and 94, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

86.

96. A monospecific antibody according to any one of claims 1-11, 94 and 95, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO:82 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

86.

97. A monospecific antibody according to any one of claims 1-11 and 94-96, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO:82 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

86.

98. The monospecific antibody of any one of claims 1-11 and 94-97, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

86.

99. The monospecific antibody of any one of claims 1-11 and 94-98, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 85; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

88.

100. A monospecific antibody according to any one of claims 1-11 and 94-99, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:82, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:83, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:84, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:85; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:86, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:87, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

88.

101. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:89 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

93.

102. The monospecific antibody of any one of claims 1-11 and 101, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

93.

103. A monospecific antibody according to any one of claims 1-11, 101 and 102, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO:89 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

93.

104. The monospecific antibody of any one of claims 1-11 and 101-103, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

93.

105. The monospecific antibody of any one of claims 1-11 and 101-104, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

93.

106. The monospecific antibody of any one of claims 1-11 and 101-105, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 92; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

95.

107. A monospecific antibody according to any one of claims 1-11 and 101-106, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 89, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 92; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 93, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

95.

108. The monospecific antibody of any one of claims 1-11 and 101-107, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 458; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 478; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

468.

109. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

100.

110. The monospecific antibody of any one of claims 1-11 and 109, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO:96 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

100.

111. A monospecific antibody according to any one of claims 1-11, 109 and 110, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO:96 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

100.

112. The monospecific antibody of any one of claims 1-11 and 109-111, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

100.

113. The monospecific antibody of any one of claims 1-11 and 109-112, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

100.

114. The monospecific antibody of any one of claims 1-11 and 109-113, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 99; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

102.

115. A monospecific antibody according to any one of claims 1-11 and 109-114, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:96, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:97, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:98, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:99; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:100, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:101, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

102.

116. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

107.

117. A monospecific antibody according to any one of claims 1-11 and 116, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

107.

118. A monospecific antibody according to any one of claims 1-11, 116 and 117, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

107.

119. The monospecific antibody of any one of claims 1-11 and 116-118, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

107.

120. The monospecific antibody of any one of claims 1-11 and 116-119, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

107.

121. A monospecific antibody according to any one of claims 1-11 and 116-120, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 106; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

109.

122. A monospecific antibody according to any one of claims 1-11 and 116-121, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 103, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 106; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 107, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

109.

123. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

114.

124. A monospecific antibody according to any one of claims 1-11 and 123, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

114.

125. A monospecific antibody according to any one of claims 1-11, 123 and 124, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

114.

126. The monospecific antibody of any one of claims 1-11 and 123-125, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

114.

127. The monospecific antibody of any one of claims 1-11 and 123-126, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

114.

128. A monospecific antibody according to any one of claims 1-11 and 123-127, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 113; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

116.

129. A monospecific antibody according to any one of claims 1-11 and 123-128, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 110, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 113; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 114, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

116.

130. The monospecific antibody of any one of claims 1-11 and 123-129, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 459; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 479; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

469.

131. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

121.

132. A monospecific antibody according to any one of claims 1-11 and 131, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

121.

133. A monospecific antibody according to any one of claims 1-11, 131 and 132, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

121.

134. The monospecific antibody of any one of claims 1-11 and 131-133, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

121.

135. The monospecific antibody of any one of claims 1-11 and 131-134, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

121.

136. A monospecific antibody according to any one of claims 1-11 and 131-135, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 120; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

123.

137. A monospecific antibody according to any one of claims 1-11 and 131-136, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 117, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 120; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 121, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

123.

138. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

128.

139. A monospecific antibody according to any one of claims 1-11 and 138, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

128.

140. The monospecific antibody of any one of claims 1-11, 138 and 139, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

128.

141. The monospecific antibody of any one of claims 1-11 and 138-140, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

128.

142. The monospecific antibody of any one of claims 1-11 and 138-141, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

128.

143. A monospecific antibody according to any one of claims 1-11 and 138-142, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 127; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

130.

144. A monospecific antibody according to any one of claims 1-11 and 138-143, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 124, and wherein the variable heavy chain (VH) region comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 127; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 128, and wherein the variable light chain (VL) region comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

131.

145. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

135.

146. A monospecific antibody according to any one of claims 1-11 and 145, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

135.

147. A monospecific antibody according to any one of claims 1-11, 145 and 146, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

135.

148. The monospecific antibody of any one of claims 1-11 and 145-147, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

135.

149. The monospecific antibody of any one of claims 1-11 and 145-148, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

135.

150. A monospecific antibody according to any one of claims 1-11 and 145-149, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 134; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

137.

151. A monospecific antibody according to any one of claims 1-11 and 145-150, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 131, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 134; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 135, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

137.

152. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

142.

153. The monospecific antibody of any one of claims 1-11 and 152, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

142.

154. A monospecific antibody according to any one of claims 1-11, 152 and 153, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

142.

155. The monospecific antibody of any one of claims 1-11 and 152-153, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

142.

156. The monospecific antibody of any one of claims 1-11 and 152-154, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

142.

157. A monospecific antibody according to any one of claims 1-11 and 152-156, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 141; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

144.

158. A monospecific antibody according to any one of claims 1-11 and 152-157, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 138, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 141; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 142, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

144.

159. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

149.

160. The monospecific antibody of any one of claims 1-11 and 159, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

149.

161. A monospecific antibody according to any one of claims 1-11, 159 and 160, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

149.

162. The monospecific antibody of any one of claims 1-11 and 159-161, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

149.

163. The monospecific antibody of any one of claims 1-11 and 159-162, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

149.

164. A monospecific antibody according to any one of claims 1-11 and 159-163, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 148; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

151.

165. A monospecific antibody according to any one of claims 1-11 and 159-164, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 145, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 148; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 149, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

151.

166. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

156.

167. A monospecific antibody according to any one of claims 1-11 and 166, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

156.

168. A monospecific antibody according to any one of claims 1-11, 166 and 167, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

156.

169. The monospecific antibody of any one of claims 1-11 and 166-168, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

156.

170. The monospecific antibody of any one of claims 1-11 and 166-169, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

156.

171. A monospecific antibody according to any one of claims 1-11 and 166-170, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 155; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

158.

172. A monospecific antibody according to any one of claims 1-11 and 166-171, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 152, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 155; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 156, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

158.

173. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

163.

174. A monospecific antibody according to any one of claims 1-11 and 173, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

163.

175. A monospecific antibody according to any one of claims 1-11, 173 and 173, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

163.

176. A monospecific antibody according to any one of claims 1-11 and 173-175, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

163.

177. The monospecific antibody of any one of claims 1-11 and 173-176, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

163.

178. A monospecific antibody according to any one of claims 1-11 and 173-177, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 162; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

165.

179. A monospecific antibody according to any one of claims 1-11 and 173-178, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 159, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 162; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 163, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

165.

180. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

170.

181. A monospecific antibody according to any one of claims 1-11 and 180, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

170.

182. A monospecific antibody according to any one of claims 1-11, 180 and 181, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

170.

183. The monospecific antibody of any one of claims 1-11 and 180-182, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

170.

184. The monospecific antibody of any one of claims 1-11 and 180-183, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

170.

185. A monospecific antibody according to any one of claims 1-11 and 180-184, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 169; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

172.

186. A monospecific antibody according to any one of claims 1-11 and 180-185, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 166, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 169; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 170, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

172.

187. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

177.

188. A monospecific antibody according to any one of claims 1-11 and 187, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

177.

189. A monospecific antibody according to any one of claims 1-11, 187 and 187-188, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

177.

190. The monospecific antibody of any one of claims 1-11 and 187-189, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

177.

191. A monospecific antibody according to any one of claims 1-11 and 187-190, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

177.

192. A monospecific antibody according to any one of claims 1-11 and 187-191, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 176; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

179.

193. A monospecific antibody according to any one of claims 1-11 and 187-192, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 173, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 176; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 177, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

179.

194. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

184.

195. A monospecific antibody according to any one of claims 1-11 and 194, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

184.

196. A monospecific antibody according to any one of claims 1-11, 194 and 195, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

184.

197. A monospecific antibody according to any one of claims 1-11 and 194-196, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

184.

198. A monospecific antibody according to any one of claims 1-11 and 194-197, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

184.

199. A monospecific antibody according to any one of claims 1-11 and 194-198, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 183; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

186.

200. A monospecific antibody according to any one of claims 1-11 and 194-199, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 180, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 183; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 184, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

186.

201. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

191.

202. A monospecific antibody according to any one of claims 1-11 and 201, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

191.

203. A monospecific antibody according to any one of claims 1-11, 201 and 202, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

191.

204. The monospecific antibody of any one of claims 1-11 and 201-203, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

191.

205. The monospecific antibody of any one of claims 1-11 and 201-204, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

191.

206. A monospecific antibody according to any one of claims 1-11 and 201-205, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 190; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

193.

207. A monospecific antibody according to any one of claims 1-11 and 201-206, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 187, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 190; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 191, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

193.

208. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

198.

209. A monospecific antibody according to any one of claims 1-11 and 208, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

198.

210. A monospecific antibody according to any one of claims 1-11, 208 and 209, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

198.

211. A monospecific antibody according to any one of claims 1-11 and 208-210, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

198.

212. The monospecific antibody of any one of claims 1-11 and 208-211, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

198.

213. A monospecific antibody according to any one of claims 1-11 and 208-212, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 197; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

200.

214. A monospecific antibody according to any one of claims 1-11 and 208-213, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 194, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 197; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 198, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

200.

215. A monospecific antibody according to any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:201 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

205.

216. A monospecific antibody according to any one of claims 1-11 and 215, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:201 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

205.

217. A monospecific antibody according to any one of claims 1-11, 215 and 216, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:201 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

205.

218. A monospecific antibody according to any one of claims 1-11 and 215-217, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:201 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

205.

219. A monospecific antibody according to any one of claims 1-11 and 215-218, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:201 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

205.

220. A monospecific antibody according to any one of claims 1-11 and 215-219, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 204; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

207.

221. A monospecific antibody according to any one of claims 1-11 and 215-220, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 201, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 204; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 205, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

207.

222. A monospecific antibody according to any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

212.

223. A monospecific antibody according to any one of claims 1-11 and 222, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

212.

224. A monospecific antibody according to any one of claims 1-11, 222 and 223, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

212.

225. A monospecific antibody according to any one of claims 1-11 and 222-224, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

212.

226. A monospecific antibody according to any one of claims 1-11 and 222-225, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

212.

227. A monospecific antibody according to any one of claims 1-11 and 222-226, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 211; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 212, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

213.

228. A monospecific antibody according to any one of claims 1-11 and 222-227, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 208, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 211; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 212, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 212, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

213.

229. A monospecific antibody according to any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

219.

230. The monospecific antibody of any one of claims 1-11 and 229, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

219.

231. A monospecific antibody according to any one of claims 1-11, 229 and 203, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:215 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

219.

232. A monospecific antibody according to any one of claims 1-11 and 229-231, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

219.

233. The monospecific antibody of any one of claims 1-11 and 229-232, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

219.

234. A monospecific antibody according to any one of claims 1-11 and 229-233, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 218; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

221.

235. A monospecific antibody according to any one of claims 1-11 and 229-234, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 215, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 218; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 219, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

221.

236. A monospecific antibody according to any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

226.

237. A monospecific antibody according to any one of claims 1-11 and 236, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

226.

238. A monospecific antibody according to any one of claims 1-11, 236 and 237, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

226.

239. A monospecific antibody according to any one of claims 1-11 and 236-238, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

226.

240. The monospecific antibody of any one of claims 1-11 and 236-239, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

226.

241. A monospecific antibody according to any one of claims 1-11 and 236-240, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 225; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

228.

242. A monospecific antibody according to any one of claims 1-11 and 236-241, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 222, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 225; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 226, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

228.

243. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

233.

244. A monospecific antibody according to any one of claims 1-11 and 243, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

233.

245. A monospecific antibody according to any one of claims 1-11, 243 and 244, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

233.

246. A monospecific antibody according to any one of claims 1-11 and 243-245, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

233.

247. The monospecific antibody of any one of claims 1-11 and 243-246, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

233.

248. A monospecific antibody according to any one of claims 1-11 and 243-247, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 232; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

235.

249. A monospecific antibody according to any one of claims 1-11 and 243-248, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 229, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 232; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 233, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

235.

250. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

240.

251. A monospecific antibody according to any one of claims 1-11 and 250, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:236 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

240.

252. A monospecific antibody according to any one of claims 1-11, 250 and 251, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

240.

253. The monospecific antibody of any one of claims 1-11 and 250-252, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

240.

254. The monospecific antibody of any one of claims 1-11 and 250-253, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

240.

255. A monospecific antibody according to any one of claims 1-11 and 250-254, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 239; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

242.

256. A monospecific antibody according to any one of claims 1-11 and 250-255, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 236, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 239; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 240, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

242.

257. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

247.

258. A monospecific antibody according to any one of claims 1-11 and 257, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

247.

259. A monospecific antibody according to any one of claims 1-11, 257 and 258, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

247.

260. The monospecific antibody of any one of claims 1-11 and 257-259, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

247.

261. A monospecific antibody according to any one of claims 1-11 and 257-260, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

247.

262. A monospecific antibody according to any one of claims 1-11 and 257-261, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 246; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

249.

263. A monospecific antibody according to any one of claims 1-11 and 257-262, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 243, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 246; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 247, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

249.

264. The monospecific antibody of any one of claims 1-11 and 257-263, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 460; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 480; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

470.

265. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

254.

266. A monospecific antibody according to any one of claims 1-11 and 265, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:250 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

254.

267. A monospecific antibody according to any one of claims 1-11, 265 and 266, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

254.

268. The monospecific antibody of any one of claims 1-11 and 265-267, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

254.

269. A monospecific antibody according to any one of claims 1-11 and 265-268, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

254.

270. A monospecific antibody according to any one of claims 1-11 and 265-269, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 253; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

256.

271. A monospecific antibody according to any one of claims 1-11 and 265-270, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 250, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 253; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 254, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

256.

272. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

261.

273. A monospecific antibody according to any one of claims 1-11 and 272, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

261.

274. A monospecific antibody according to any one of claims 1-11, 272 and 273, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

261.

275. A monospecific antibody according to any one of claims 1-11 and 272-274, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

261.

276. A monospecific antibody according to any one of claims 1-11 and 272-275, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

261.

277. A monospecific antibody according to any one of claims 1-11 and 272-276, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 260; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

263.

278. A monospecific antibody according to any one of claims 1-11 and 272-277, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 257, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 260; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 261, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

263.

279. A monospecific antibody according to any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

268.

280. The monospecific antibody of any one of claims 1-11 and 279, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

268.

281. A monospecific antibody according to any one of claims 1-11, 279 and 280, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

268.

282. A monospecific antibody according to any one of claims 1-11 and 279-281, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

268.

283. The monospecific antibody of any one of claims 1-11 and 279-282, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

268.

284. A monospecific antibody according to any one of claims 1-11 and 279-283, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 267; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

270.

285. A monospecific antibody according to any one of claims 1-11 and 279-284, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 264, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 267; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 268, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

270.

286. A monospecific antibody according to any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

275.

287. A monospecific antibody according to any one of claims 1-11 and 286, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

275.

288. A monospecific antibody according to any one of claims 1-11, 286 and 287, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

275.

289. A monospecific antibody according to any one of claims 1-11 and 286-288, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

275.

290. The monospecific antibody of any one of claims 1-11 and 286-289, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

275.

291. A monospecific antibody according to any one of claims 1-11 and 286-290, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 274; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

277.

292. A monospecific antibody according to any one of claims 1-11 and 286-291, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 271, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 274; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 275, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

277.

293. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

282.

294. A monospecific antibody according to any one of claims 1-11 and 293, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

282.

295. A monospecific antibody according to any one of claims 1-11, 293 and 294, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

282.

296. A monospecific antibody according to any one of claims 1-11 and 293-295, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

282.

297. A monospecific antibody according to any one of claims 1-11 and 293-296, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

282.

298. A monospecific antibody according to any one of claims 1-11 and 293-297, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 281; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

284.

299. A monospecific antibody according to any one of claims 1-11 and 293-298, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 278, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 281; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 282, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

284.

300. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

289.

301. The monospecific antibody of any one of claims 1-11 and 300, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

289.

302. A monospecific antibody according to any one of claims 1-11, 300 and 301, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

289.

303. The monospecific antibody of any one of claims 1-11 and 300-302, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

289.

304. The monospecific antibody of any one of claims 1-11 and 300-303, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

289.

305. The monospecific antibody of any one of claims 1-11 and 300-304, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 288; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

291.

306. A monospecific antibody according to any one of claims 1-11 and 300-305, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 285, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 288; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 289, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

291.

307. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

296.

308. A monospecific antibody according to any one of claims 1-11 and 307, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

296.

309. A monospecific antibody according to any one of claims 1-11, 307 and 308, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

296.

310. The monospecific antibody of any one of claims 1-11 and 307-309, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

296.

311. The monospecific antibody of any one of claims 1-11 and 307-310, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

296.

312. A monospecific antibody according to any one of claims 1-11 and 307-311, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 295; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

298.

313. A monospecific antibody according to any one of claims 1-11 and 307-312, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 292, and wherein the variable heavy chain (VH) region comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 295; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 296, and wherein the variable light chain (VL) region comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

298.

314. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

303.

315. A monospecific antibody according to any one of claims 1-11 and 314, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

303.

316. A monospecific antibody according to any one of claims 1-11, 314 and 315, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

303.

317. A monospecific antibody according to any one of claims 1-11 and 314-316, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

303.

318. The monospecific antibody of any one of claims 1-11 and 314-317, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

303.

319. A monospecific antibody according to any one of claims 1-11 and 314-318, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 302; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

305.

320. A monospecific antibody according to any one of claims 1-11 and 314-319, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 299, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 302; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 303, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

305.

321. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

310.

322. A monospecific antibody according to any one of claims 1-11 and 321, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

310.

323. A monospecific antibody according to any one of claims 1-11, 321 and 322, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

310.

324. The monospecific antibody of any one of claims 1-11 and 321-323, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

310.

325. The monospecific antibody of any one of claims 1-11 and 321-324, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

310.

326. A monospecific antibody according to any one of claims 1-11 and 321-325, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 309; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

312.

327. A monospecific antibody according to any one of claims 1-11 and 321-326, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 306, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 309; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 310, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

312.

328. The monospecific antibody of any one of claims 1-11 and 321-327, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 461; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 481; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

471.

329. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

317.

330. The monospecific antibody of any one of claims 1-11 and 329, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

317.

331. A monospecific antibody according to any one of claims 1-11, 329 and 330, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

317.

332. The monospecific antibody of any one of claims 1-11 and 329-331, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

317.

333. The monospecific antibody of any one of claims 1-11 and 329-332, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

317.

334. A monospecific antibody according to any one of claims 1-11 and 329-333, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 316; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

319.

335. A monospecific antibody according to any one of claims 1-11 and 329-334, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 313, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 316; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 317, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

319.

336. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

324.

337. A monospecific antibody according to any one of claims 1-11 and 336, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

324.

338. A monospecific antibody according to any one of claims 1-11, 336 and 337, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

324.

339. The monospecific antibody of any one of claims 1-11 and 336-338, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

324.

340. The monospecific antibody of any one of claims 1-11 and 336-339, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

324.

341. A monospecific antibody according to any one of claims 1-11 and 336-340, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 323; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

326.

342. A monospecific antibody according to any one of claims 1-11 and 336-341, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 320, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 323; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 324, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

326.

343. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

331.

344. A monospecific antibody according to any one of claims 1-11 and 343, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

331.

345. A monospecific antibody according to any one of claims 1-11, 343 and 344, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

331.

346. The monospecific antibody of any one of claims 1-11 and 343-345, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

331.

347. The monospecific antibody of any one of claims 1-11 and 343-346, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

331.

348. A monospecific antibody according to any one of claims 1-11 and 343-347, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 330; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

333.

349. A monospecific antibody according to any one of claims 1-11 and 343-348, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 327, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 330; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 331, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

333.

350. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

338.

351. A monospecific antibody according to any one of claims 1-11 and 350, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

338.

352. A monospecific antibody according to any one of claims 1-11, 350 and 351, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

338.

353. The monospecific antibody of any one of claims 1-11 and 350-352, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

338.

354. The monospecific antibody of any one of claims 1-11 and 350-353, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

338.

355. The monospecific antibody of any one of claims 1-11 and 350-354, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 337; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

340.

356. A monospecific antibody according to any one of claims 1-11 and 350-355, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 334, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 337; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 338, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

340.

357. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

345.

358. A monospecific antibody according to any one of claims 1-11 and 357, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

345.

359. A monospecific antibody according to any one of claims 1-11, 357 and 358, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

345.

360. The monospecific antibody of any one of claims 1-11 and 357-359, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

345.

361. A monospecific antibody according to any one of claims 1-11 and 357-360, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

345.

362. A monospecific antibody according to any one of claims 1-11 and 357-361, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 344; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

347.

363. A monospecific antibody according to any one of claims 1-11 and 357-362, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 341, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 344; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 345, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

347.

364. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

352.

365. A monospecific antibody according to any one of claims 1-11 and 364, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:348 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

352.

366. A monospecific antibody according to any one of claims 1-11, 364 and 365, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

352.

367. A monospecific antibody according to any one of claims 1-11 and 364-366, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

352.

368. A monospecific antibody according to any one of claims 1-11 and 364-367, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

352.

369. A monospecific antibody according to any one of claims 1-11 and 364-368, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 351; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

354.

370. A monospecific antibody according to any one of claims 1-11 and 364-369, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 348, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 351; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 352, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

354.

371. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

359.

372. A monospecific antibody according to any one of claims 1-11 and 371, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:355 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

359.

373. A monospecific antibody according to any one of claims 1-11, 371 and 372, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:355 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

359.

374. The monospecific antibody of any one of claims 1-11 and 371-373, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

359.

375. A monospecific antibody according to any one of claims 1-11 and 371-374, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:355 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

359.

376. A monospecific antibody according to any one of claims 1-11 and 371-375, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 358; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

361.

377. A monospecific antibody according to any one of claims 1-11 and 371-378, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 355, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 358; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 359, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

361.

378. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

366.

379. A monospecific antibody according to any one of claims 1-11 and 378, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

366.

380. The monospecific antibody of any one of claims 1-11, 378 and 379, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

366.

381. The monospecific antibody of any one of claims 1-11 and 378-380, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

366.

382. The monospecific antibody of any one of claims 1-11 and 378-381, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

366.

383. A monospecific antibody according to any one of claims 1-11 and 378-382, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 365; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

368.

384. A monospecific antibody according to any one of claims 1-11 and 378-383, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 362, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 365; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 366, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

368.

385. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

373.

386. A monospecific antibody according to any one of claims 1-11 and 385, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

373.

387. A monospecific antibody according to any one of claims 1-11, 385 and 386, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

373.

388. The monospecific antibody of any one of claims 1-11 and 385-387, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

373.

389. A monospecific antibody according to any one of claims 1-11 and 385-388, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

373.

390. A monospecific antibody according to any one of claims 1-11 and 385-389, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 372; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

375.

391. A monospecific antibody according to any one of claims 1-11 and 385-380, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 369, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 372; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 373, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

375.

392. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

380.

393. A monospecific antibody according to any one of claims 1-11 and 392, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

380.

394. A monospecific antibody according to any one of claims 1-11, 392 and 393, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

380.

395. A monospecific antibody according to any one of claims 1-11 and 392-394, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

380.

396. A monospecific antibody according to any one of claims 1-11 and 392-395, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

380.

397. A monospecific antibody according to any one of claims 1-11 and 392-396, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 379; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

382.

398. A monospecific antibody according to any one of claims 1-11 and 392-397, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 376, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 379; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 380, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

382.

399. A monospecific antibody according to any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:

387.

400. The monospecific antibody of any one of claims 1-11 and 399, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

387.

401. A monospecific antibody according to any one of claims 1-11, 399 and 400, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

387.

402. The monospecific antibody of any one of claims 1-11 and 399-401, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

387.

403. The monospecific antibody of any one of claims 1-11 and 399-402, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

387.

404. A monospecific antibody according to any one of claims 1-11 and 399-403, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 386; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

389.

405. A monospecific antibody according to any one of claims 1-11 and 399-404, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 383, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 386; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 387, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

389.

406. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

394.

407. The monospecific antibody of any one of claims 1-11 and 406, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

394.

408. The monospecific antibody of any one of claims 1-11, 406 and 407, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

394.

409. The monospecific antibody of any one of claims 1-11 and 406-408, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

394.

410. The monospecific antibody of any one of claims 1-11 and 406-409, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

394.

411. A monospecific antibody according to any one of claims 1-11 and 406-410, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 393; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

396.

412. A monospecific antibody according to any one of claims 1-11 and 406-411, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 390, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 393; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 394, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

396.

413. The monospecific antibody of any one of claims 1-11 and 406-412, wherein the antibody comprises: a first heavy chain (HC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 462; a second heavy chain region comprising an amino acid sequence at least 80% identical to SEQ ID NO: 482; and a light chain (LC) region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

472.

414. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

401.

415. A monospecific antibody according to any one of claims 1-11 and 414, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

401.

416. A monospecific antibody according to any one of claims 1-11, 414 and 415, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

401.

417. The monospecific antibody of any one of claims 1-11 and 414-416, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

401.

418. The monospecific antibody of any one of claims 1-11 and 414-417, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

401.

419. A monospecific antibody according to any one of claims 1-11 and 414-418, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 400; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

403.

420. A monospecific antibody according to any one of claims 1-11 and 414-419, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 397, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 400; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 401, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

403.

421. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:404 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

408.

422. A monospecific antibody according to any one of claims 1-11 and 421, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:404 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

408.

423. A monospecific antibody according to any one of claims 1-11, 421 and 422, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:404 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

408.

424. The monospecific antibody of any one of claims 1-11 and 421-423, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

408.

425. The monospecific antibody of any one of claims 1-11 and 421-424, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:404 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

408.

426. A monospecific antibody according to any one of claims 1-11 and 421-425, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 407; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

410.

427. A monospecific antibody according to any one of claims 1-11 and 421-426, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:404, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:405, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:406, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:407; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:408, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:409, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

410.

428. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:411 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

415.

429. A monospecific antibody according to any one of claims 1-11 and 428, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO:411 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

415.

430. A monospecific antibody according to any one of claims 1-11, 428 and 428, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:411 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

415.

431. The monospecific antibody of any one of claims 1-11 and 428-430, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO:411 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

415.

432. The monospecific antibody of any one of claims 1-11 and 428-431, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:411 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

415.

433. A monospecific antibody according to any one of claims 1-11 and 428-432, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 414; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

417.

434. A monospecific antibody according to any one of claims 1-11 and 428-433, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:411, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:412, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:413, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:414; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:415, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:416, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

417.

435. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:418 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

422.

436. A monospecific antibody according to any one of claims 1-11 and 435, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:418 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

422.

437. A monospecific antibody according to any one of claims 1-11, 435 and 436, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:418 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

422.

438. The monospecific antibody of any one of claims 1-11 and 435-437, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

422.

439. A monospecific antibody according to any one of claims 1-11 and 435-438, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:418 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

422.

440. A monospecific antibody according to any one of claims 1-11 and 435-439, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 421; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

424.

441. A monospecific antibody according to any one of claims 1-11 and 435-440, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:418, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:419, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:420, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:421; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:422, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:423, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

424.

442. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

429.

443. A monospecific antibody according to any one of claims 1-11 and 442, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:425 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

429.

444. A monospecific antibody according to any one of claims 1-11, 442 and 443, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:425 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

429.

445. The monospecific antibody of any one of claims 1-11 and 442-444, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO:425 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

429.

446. The monospecific antibody of any one of claims 1-11 and 442-445, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:425 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

429.

447. A monospecific antibody according to any one of claims 1-11 and 442-446, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 428; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

431.

448. A monospecific antibody according to any one of claims 1-11 and 442-447, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 425, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 428; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 429, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

431.

449. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

436.

450. The monospecific antibody of any one of claims 1-11 and 449, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

436.

451. A monospecific antibody according to any one of claims 1-11, 449 and 450, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:432 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

436.

452. The monospecific antibody of any one of claims 1-11 and 449-451, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

436.

453. The monospecific antibody of any one of claims 1-11 and 449-452, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

436.

454. A monospecific antibody according to any one of claims 1-11 and 449-453, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 435; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

438.

455. A monospecific antibody according to any one of claims 1-11 and 449-454, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 432, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 435; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 436, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

438.

456. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

443.

457. The monospecific antibody of any one of claims 1-11 and 456, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO:439 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

443.

458. A monospecific antibody according to any one of claims 1-11, 456 and 457, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:439 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

443.

459. The monospecific antibody of any one of claims 1-11 and 456-458, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

443.

460. The monospecific antibody of any one of claims 1-11 and 456-459, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

443.

461. A monospecific antibody according to any one of claims 1-11 and 456-460, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 442; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

445.

462. A monospecific antibody according to any one of claims 1-11 and 456-461, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:439, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:440, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:441, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:442; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:443, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:444, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

445.

463. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:446 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

450.

464. A monospecific antibody according to any one of claims 1-11 and 463, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:446 and a variable light chain (VL) region having an amino acid sequence that is at least 85% identical to SEQ ID NO:

450.

465. A monospecific antibody according to any one of claims 1-11, 463 and 464, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:446 and a variable light chain (VL) region having an amino acid sequence that is at least 90% identical to SEQ ID NO:

450.

466. A monospecific antibody according to any one of claims 1-11 and 463-465, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:446 and a variable light chain (VL) region having an amino acid sequence that is at least 95% identical to SEQ ID NO:

450.

467. A monospecific antibody according to any one of claims 1-11 and 463-466, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:446 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

450.

468. A monospecific antibody according to any one of claims 1-11 and 463-467, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 449; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

452.

469. A monospecific antibody according to any one of claims 1-11 and 463-468, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 446, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 449; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO: 450, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

452.

470. The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical to SEQ ID NO:61 and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:

65.

471. A monospecific antibody according to any one of claims 1-11 and 470, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical to SEQ ID NO:61 and a variable light chain (VL) region having an amino acid sequence at least 85% identical to SEQ ID NO:

65.

472. The monospecific antibody of any one of claims 1-11, 470, and 470-471, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical to SEQ ID NO:61 and a variable light chain (VL) region having an amino acid sequence at least 90% identical to SEQ ID NO:

65.

473. The monospecific antibody of any one of claims 1-11 and 470-472, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% identical to SEQ ID NO:61 and a variable light chain (VL) region having an amino acid sequence at least 95% identical to SEQ ID NO:

65.

474. The monospecific antibody of any one of claims 1-11 and 470-473, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:61 and a variable light chain (VL) region having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

65.

475. A monospecific antibody according to any one of claims 1-11 and 470-474, wherein the antibody comprises: a VH comprising a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:62, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:63, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:64; and a VL comprising a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:66, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

67.

476. A monospecific antibody according to any one of claims 1-11 and 470-475, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:61, and wherein it comprises a complementarity determining region (CDR) H1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:62, a CDR H2 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:63, and a CDR H3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:64; a variable light chain (VL) region having an amino acid sequence that is at least 80% identical to SEQ ID NO:65, and wherein it comprises a complementarity determining region (CDR) L1 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:66, a CDR L2 having an amino acid sequence that is 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

67.

477. The monospecific antibody of any one of claims 1-476, wherein the antibody binds to one or more amino acid residues of the VWFCK domain selected from D2726, R2730, K2735, E2744, D2746, K2757, D2763 and T2789.

478. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: D2726, R2730, D2746 and K2757.

479. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: R2730, K2735, E2744, and D2746.

480. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: K2735, D2746, and K2757.

481. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: R2730, D2746, and K2757.

482. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: K2735, E2744, D2746, and D2763.

483. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: R2730, K2735, E2744, D2746, K2757 and D2763.

484. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least amino acid residue K2735 of the VWFCK domain.

485. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: D2726, K2735, and K2757.

486. The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWFCK domain: K2735 and D2763.

487. The monospecific antibody of any one of claims 1-486, wherein binding of the antibody to the VWF protein does not result in a functional change of the VWF protein.

488. The monospecific antibody of any one of claims 1-487, wherein binding of the antibody to the VWF protein does not inhibit binding of the VWF protein to one or more binding partners.

489. The monospecific antibody of claim 488, wherein the one or more binding partners are selected from the group consisting of Factor VIII, collagen, glycoprotein Ib (gp1b), glycoprotein IIb / IIIa (gpIIb / IIIa), and ADAM metallopeptidase with type 1 thrombospondin motif 13 (ADAMTS13).

490. The monospecific antibody of any one of claims 487-489, wherein binding of the antibody to the VWF protein does not inhibit binding of the VWF protein to platelet cells.

491. The monospecific antibody of any one of claims 1-490, wherein accumulation of the VWF protein in plasma results in plasma levels of the VWF protein that are at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold higher than the plasma level of the VWF protein in the absence of the antibody.

492. The monospecific antibody of any one of claims 1-490, wherein accumulation of the VWF protein in the plasma results in a plasma level of the VWF protein of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 700%, 800%, 900%, 1000%, 1500%, 2000%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 7000%, 8 ... %, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000% or more.

493. The monospecific antibody of any one of claims 1-492, wherein binding of said antibody to said VWF protein in plasma increases the plasma half-life of said VWF protein compared to the plasma half-life of said VWF protein in the absence of said antibody.

494. The monospecific antibody of claim 493, wherein binding of the antibody to the VWF protein in plasma increases the plasma half-life of the VWF protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold or more compared to the plasma half-life of the VWF protein in the absence of the antibody.

495. The monospecific antibody of claim 493, wherein binding of the antibody to the VWF protein in plasma increases the plasma half-life of the VWF protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 700%, 800%, 900%, 1000%, 1500%, 2000%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 7000%, 8 ... %, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500% or 10,000% or more.

496. The monospecific antibody of any one of claims 1-495, wherein binding of the antibody to VWF protein in plasma results in accumulation of Factor VIII (FVIII) protein in plasma compared to plasma levels of FVIII protein in the absence of the antibody.

497. The monospecific antibody of claim 496, wherein accumulation of the FVIII protein in plasma results in plasma levels of the Factor VIII protein that are at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold higher than the plasma level of the FVIII protein in the absence of the antibody.

498. The monospecific antibody of claim 496, wherein accumulation of the FVIII protein in plasma results in a plasma level of the FVIII protein of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 700%, 800%, 900%, 1000%, 1500%, 2000%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 7000%, 8 ... %, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000% or more.

499. The monospecific antibody of any one of claims 1-598, wherein binding of the antibody to the VWF protein in plasma increases the plasma half-life of the FVIII protein compared to the plasma half-life of the FVIII protein in the absence of the antibody.

500. The monospecific antibody of claim 499, wherein binding of the antibody to the VWF protein in plasma increases the plasma half-life of the FVIII protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold or more compared to the plasma half-life of the FVIII protein in the absence of the antibody.

501. The monospecific antibody of claim 499, wherein binding of the antibody to the VWF protein in plasma increases the plasma half-life of the FVIII protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550% compared to the plasma half-life of the FVIII protein in the absence of the antibody. %, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500% or 10,000% or more.

502. The monospecific antibody of any one of claims 1-501, wherein the antibody specifically binds to a VWF homodimer with a 1:1 stoichiometry, the VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linker.

503. The monospecific antibody of any one of claims 1-501, wherein the antibody specifically binds to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linkage at a 2:1 stoichiometry.

504. The monospecific antibody of any one of claims 1-503, wherein the antibody has a dissociation constant (K) of less than 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 7 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.25 nM, 0.1 nM, 0.075 nM, 0.05 nM, 0.025 nM, 0.01 nM or less. d ) binds to the CK domain of the VWF protein.

505. The monospecific antibody of any one of claims 1-504, wherein the antibody cross-reacts with VWF protein of cynomolgus monkey (Macaca fascicularis), house mouse (Mus musculus) and / or domestic dog (Canis familiaris).

506. The monospecific antibody of claim 505, wherein the antibody exhibits an affinity for VWF protein of cynomolgus monkey, musculus musculus and / or canis canis that is at most 10-fold lower than the affinity of the antibody for human VWF protein.

507. The monospecific antibody of any one of claims 1-506, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

508. The monospecific antibody of any one of claims 1-507, wherein the CK domain has the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO:

6.

509. A complex comprising a VWF protein and the monospecific antibody of any one of claims 1-508.

510. A pharmaceutical composition comprising the monospecific antibody of any one of claims 1-508 and a pharmaceutically acceptable carrier, diluent or excipient.

511. The pharmaceutical composition of claim 510, wherein the pharmaceutically acceptable carrier, diluent or excipient is selected from the group consisting of a stabilizer, a buffer, a surfactant, a filler, a solvent, a tonicity or osmotic pressure regulator, an antioxidant, an adjuvant and an antimicrobial agent.

512. A method of treating a blood disorder characterized by excessive bleeding in a subject in need thereof, comprising administering to the subject the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

513. The method of claim 512, wherein the blood disorder is selected from the group consisting of von Willebrand disease (VWD), Heydes syndrome, hemophilia A, platelet dysfunction, and connective tissue disorders.

514. The method of claim 513, wherein the VWD is congenital VWD (cVWD) or acquired VWD (aVWD).

515. The method of claim 513 or 514, wherein the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

516. The method of any one of claims 512-515, wherein the composition treats one or more symptoms of a blood disorder selected from the group consisting of epistaxis, skin bleeding, bleeding from minor wounds, oral bleeding, angiodysplasia, gastrointestinal bleeding, tooth extraction bleeding, postoperative bleeding, heavy menstrual bleeding, obstetric bleeding, hematuria, muscle hematomas, joint bleeding, visceral bleeding, and central nervous system (CNS) bleeding.

517. The method of any one of claims 512-516, wherein the composition or pharmaceutical composition promotes platelet adhesion and / or aggregation in the subject.

518. A method of accumulating VWF protein in the plasma of a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

519. A method of accumulating FVIII protein in the plasma of a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

520. A method of increasing the plasma half-life of a VWF protein in a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

521. The method of any one of claims 512-520, wherein the composition is a pharmaceutical composition comprising the monospecific antibody and a pharmaceutically acceptable carrier, diluent or excipient.

522. The method of claim 521, wherein the pharmaceutically acceptable carrier, diluent or excipient is selected from the group consisting of a stabilizer, a buffer, a surfactant, a filler, a solvent, a tonicity or osmotic pressure regulator, an antioxidant, an adjuvant and an antimicrobial agent.

523. The method of any one of claims 512-522, wherein the composition or the pharmaceutical composition is administered in combination with one or more additional therapeutic modalities.

524. The method of claim 523, wherein the one or more additional treatment modalities are selected from the group consisting of: desmopressin (DDAVP), tranexamic acid (TXA), thalidomide, tamoxifen, octreotide, plasma-derived VWF protein concentrate, VWF protein concentrate complexed with FVIII protein, recombinant VWF protein concentrate, FVIII protein concentrate, hormone therapy, gene therapy, blood transfusion, platelet transfusion, surgery, and cautery.

525. The method of claim 524, wherein the gene therapy is FVIII gene therapy.

526. The method of any one of claims 523-525, wherein the one or more additional therapeutic modalities are administered to the subject before, simultaneously with, or after administration of the composition or the pharmaceutical composition.

527. The method of any one of claims 512-526, wherein the subject is human.

528. A kit comprising the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claims 510 or 511, and a package insert instructing the user of the kit to perform the method of any one of claims 512-527.

529. The monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511 for use as a medicament.

530. The monospecific antibody or pharmaceutical composition of claim 529 for use in treating a blood disorder characterized by excessive bleeding.

531. The monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511, for use in treating a blood disorder characterized by excessive bleeding.

532. The monospecific antibody or pharmaceutical composition for use according to claim 530 or 531, wherein the blood disorder characterized by excessive bleeding is selected from the group consisting of: VWD, Heydes syndrome, hemophilia A, platelet dysfunction, and connective tissue disorders.

533. The monospecific antibody or pharmaceutical composition for use according to claim 532, wherein the VWD is cVWD or aVWD.

534. The monospecific antibody or pharmaceutical composition for use according to claim 532 or 533, wherein the VWD is type 1, type 2A, type 2B, type 2M, type 2N or type 3.